Physician profile

Karan S Bhalla

Cardiovascular Disease · Pasadena, TX

NPI 1407902794

$39,608.87

in general payments reported to CMS, 2019-2025

48 companies · $6,899 in 2025

The $6,899 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$15,781.25
Food and Beverage$5,181.02
Travel and Lodging$1,616.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $24,161.98 2019-2025 General - Therapies, Lux-Dx Insertable Cardiac Monitor, Vigilant X4 Crt-D
Bard Peripheral Vascular, INC. $4,903.37 2019-2022
Medtronic Vascular, INC. $1,398.42 2019-2020
Medtronic, INC. $1,012.65 2021-2025 Corevalve Evolut R, Linq II, Closurefast
Novartis Pharmaceuticals Corporation $969.41 2019-2025
Terumo Medical Corporation $916.10 2019-2020
Cardiovascular Systems INC. $639.88 2019-2020
Janssen Pharmaceuticals, INC $588.62 2019-2022
Venclose INC. $579.76 2020
Astrazeneca Pharmaceuticals LP $433.79 2019-2025 Farxiga
Pfizer INC. $379.81 2019-2025
Tactile Systems Technology INC $334.26 2019-2023 Entre Plus, Flexitouch Plus
Abbott Laboratories $288.43 2021-2023 Thoratec Heartmate 3 Lvas Implant Kit
Philips North America LLC $281.43 2019
Merck Sharp & Dohme LLC $267.25 2021-2023 Verquvo
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $207.96 2019-2025 Repatha, Repatha
Atricure, INC. $206.40 2021
Boehringer Ingelheim Pharmaceuticals, INC. $200.55 2019-2025 Jardiance
Baxter Healthcare $192.92 2023 Hillrom - Carnation Ambulatory Monitor
Amarin Pharma, INC. $183.29 2019
Heartflow, INC. $182.81 2022-2025 Ffrct
E.R. Squibb & Sons, L.L.C. $154.60 2019-2022
Biosense Webster, INC. $145.04 2024-2025 Carto 3
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $144.82 2019-2023 Lifevest
Sanofi-Aventis U.S. LLC $133.54 2019-2024
Impulse Dynamics (USA) INC. $110.95 2023 Optimizer
Angiodynamics, INC. $103.84 2019-2021
Esperion Therapeutics, INC. $61.97 2021
Edwards Lifesciences Corporation $58.96 2023 Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Kiniksa Pharmaceuticals International, Plc $47.18 2024 Arcalyst
Inspire Medical Systems, INC. $43.14 2025 Inspire
Kiniksa Pharmaceuticals, LTD. $41.61 2023 Arcalyst
Regeneron Healthcare Solutions, INC. $33.04 2019
Scpharmaceuticals INC. $22.17 2025
Actelion Pharmaceuticals US, INC. $21.62 2022
Itamar Medical INC $19.07 2024 Watchpatone
Cook Medical LLC $17.55 2022
Bracco Diagnostics INC. $17.35 2023
Qorumpartners $17.31 2022
Novo Nordisk INC $16.84 2024 Rybelsus, Ozempic
Irhythm Technologies, INC. $16.20 2023 Zio Xt Patch
Lexicon Pharmaceuticals, INC. $15.57 2023 Inpefa
Cordis US Corp. $13.80 2023 Brite Tip Radianz
Bardy Diagnostics, INC. $12.00 2019
Biocompatibles, INC. $11.61 2019

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$27,400.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

$1,025,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Karan S Bhalla

$39,608.87

in general payments reported 2019-2025

Years
2019-2025
Top company
Vifor (International) LTD.
Context
The $6,899 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/200264/karan-s-bhalla

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.